The Importance of Testosterone Control in Prostate Cancer
- 30 September 2007
- journal article
- review article
- Published by Elsevier in European Urology Supplements
- Vol. 6 (15) , 834-839
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- Bone and prostate cancer cell interactions in metastatic prostate cancerBJU International, 2006
- The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlightBJU International, 2006
- Testosterone and Prostate Cancer: An Historical Perspective on a Modern MythEuropean Urology, 2006
- Time course of serum testosterone and luteinizing hormone levels after cessation of long‐term luteinizing hormone‐releasing hormone agonist treatment in patients with prostate cancerThe Prostate, 2005
- Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?Journal of Clinical Oncology, 2005
- Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment With Monthly and 3-month Depot Formulations of Leuprolide Acetate for Advanced Prostate CancerJournal of Urology, 2002
- Clinical Pharmacokinetics of Depot LeuprorelinClinical Pharmacokinetics, 2002
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999
- Effect of Orchidectomy on Serum Concentrations of Testosterone and Dihydrotestosterone in Patients with Prostatic CancerScandinavian Journal of Urology and Nephrology, 1992